Kringle Pharma, Net Income Forecast for the Fiscal Year Loss to Narrow

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Wed Jul 16, 2025 4:15 pm JST Revision

4884 Kringle Pharma,Inc. 【J-GAAP】

Guidance Update Report

Kringle Pharma,Inc. <4884> [TSE Growth] announced a performance revision after the market closed on July 16th (16:15). The net income/loss (non-consolidated) forecast for the fiscal year ending September 2025 has been revised upward from an expected loss of 1.38 billion yen to a loss of 0.94 billion yen (compared to a loss of 0.75 billion yen in the previous period), indicating a reduction in the loss margin.

Based on the upwardly revised full-year plan announced by the company, our calculation indicates that the April to September period (second half) net income/loss has been revised upward from an expected loss of 0.86 billion yen to a loss of 0.43 billion yen (compared to a loss of 0.39 billion yen in the same period of the previous year), indicating a reduction in the loss margin.

Kabutan News

Guidance Update

Second Half Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Apr - Sep, 2025 Prev	237	-868	-868	-868	-124.0	0	May 12, 2025	J-GAAP
Apr - Sep, 2025 New	36	-428	-434	-434	-62.0	0	Jul 16, 2025	J-GAAP
Revision Rate	-84.8%	+50.7%	+50.0%	+50.0%	+50.0%

Full Year Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Sep, 2025 Prev	272	-1,379	-1,379	-1,380	-197.2	0	Nov 13, 2024	J-GAAP
Sep, 2025 New	71	-939	-945	-946	-135.2	0	Jul 16, 2025	J-GAAP
Revision Rate	-73.9%	+31.9%	+31.5%	+31.4%	+31.5%

Current Period Guidance

Second Half Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Apr - Sep, 2024	37	-451	-389	-390	-61.0	0	Nov 13, 2024	J-GAAP
Apr - Sep, 2025 Guidance	36	-428	-434	-434	-62.0	0	Jul 16, 2025	J-GAAP
YoY	-2.7%	+5.1%	-11.6%	-11.3%	-1.7%

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Sep, 2023	69	-888	-852	-854	-158.5	0	Nov 13, 2023	J-GAAP
Sep, 2024	80	-817	-754	-756	-118.2	0	Nov 13, 2024	J-GAAP
Sep, 2025 Guidance	71	-939	-945	-946	-135.2	0	Jul 16, 2025	J-GAAP
YoY	-11.3%	-14.9%	-25.3%	-25.1%	-14.3%